Biofrontera AG is currently in negotiations with its US-based subsidiary, Biofrontera Inc., regarding the existing license and supply agreement between the two companies. These discussions, which were announced on June 10, 2025, are considering various strategic options that could lead to significant changes in their cooperation. As part of these negotiations, a deferral of a claim amounting to EUR 1.8 million from Biofrontera Group against Biofrontera Inc. has been agreed upon. The outcome of these talks may result in Biofrontera AG adjusting its business model and strategic orientation in the near future.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.